Perspectives
Botox for migraines: waste, high cost, and low adherence
Botox® is not much help either
August 21, 2019Finding the right treatment can be a real headache for migraine patients; for those who finally try it, it doesn’t look like Botox® is much help either
Patients who try Botox have not responded to other conventional migraine therapies. They have struggled to find relief from acute, debilitating headaches. This study looked at 2,500 patients who were new to Botox therapy. Treatment consists of injections given in the face, head and neck by a doctor in a health care setting.
Waste: Because of vial sizes and dosing, there is substantial drug waste. Drug waste and provider administration accounts for one-third of the drug’s $6,300 annual cost. Low adherence: Less than half of the patients completed the recommended four courses of quarterly treatments. This indicates treatment failure. High cost: The study found that Botox did not decrease total cost of care for patients with migraines. It was associated with a three-fold increase in total migraine-related costs.
Related news
Perspectives
April 25, 2024
Drug Approvals Monthly Update: April 2024
This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…
Perspectives
April 24, 2024
Prime/MRx resident wins AMCP Foundation Best Poster Award
Ai Quynh Nguyen, PharmD, was recently recognized for her research on opioid-prescribing patterns and outcomes
Perspectives
April 23, 2024
Expert Clinical Network Insights: April 2024
A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance